The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells

BACKGROUND: Chemotherapy remains a major clinical option for the successful treatment of cancer by eliminating fast-growing populations of cancer cells. However, drug resistance causes the failure of antitumor treatment. Increasing evidence suggests that a small subpopulation of cancer cells will en...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Li, Yang, Qian, Peng, Shaoyong, Liu, Xiaoxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635829/
https://www.ncbi.nlm.nih.gov/pubmed/31371980
http://dx.doi.org/10.2147/OTT.S212465

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635829/
https://www.ncbi.nlm.nih.gov/pubmed/31371980
http://dx.doi.org/10.2147/OTT.S212465

Ejemplares similares